(Q38786102)

6 September 2017

Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge (English)

1 reference

6 September 2017

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27007660%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Giulia Valeria Bianchi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27007660%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Elda Tagliabue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27007660%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Tiziana Triulzi

1

1 reference

6 September 2017

Giulia Valeria Bianchi

2

1 reference

6 September 2017

Elda Tagliabue

3

1 reference

6 September 2017

language of work or name

English

0 references

publication date

23 March 2016

1 reference

6 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27007660%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27007660%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27007660%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

1413-1428

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27007660%20AND%20SRC:MED&resulttype=core&format=json

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

HER2 as a target for breast cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Activity and resistance of trastuzumab according to different clinical settings.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Noncanonical roles of the immune system in eliciting oncogene addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Immunological aspects of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Protein ectodomain shedding

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Role of exon-16-deleted HER2 in breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Mammary tumor formation and metastasis evoked by a HER2 splice variant

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

PIK3CA genotype and treatment decisions in human epidermal growth factor receptor 2-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Comprehensive molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Clinical implications of the intrinsic molecular subtypes of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Immune Signature to Predict Trastuzumab Benefit: Potential and Pitfalls.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

The immune system and response to HER2-targeted treatment in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Reply to P.G. Gavin et al.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0025

21 January 2018

Identifiers

DOI

10.2217/FON-2015-0025

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27007660%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference